UBS Group
ANRO icon

UBS Group’s Alto Neuroscience ANRO Stock Holding History

UBS Group’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$388K Sell
17,250
-1,239
-7% -$23K ﹤0.01% 6252
2025
Q4 		$329K Sell
18,489
-120,542
-87% -$1.52M ﹤0.01% 6306
2025
Q3 		$559K Sell
139,031
-289,185
-68% -$959K ﹤0.01% 6011
2025
Q2 		$942K Sell
428,216
-81,994
-16% -$195K ﹤0.01% 5499
2025
Q1 		$1.1M Buy
510,210
+107,813
+27% +$386K ﹤0.01% 5203
2024
Q4 		$1.7M Buy
402,397
+367,389
+1,049% +$2.29M ﹤0.01% 4879
2024
Q3 		$400K Buy
35,008
+32,318
+1,201% +$396K ﹤0.01% 5383
2024
Q2 		$28.8K Buy
2,690
+1,823
+210% +$23.7K ﹤0.01% 7086
2024
Q1 		$13.3K Buy
+867
New +$13.6K ﹤0.01% 7109

Other funds holding ANRO

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group's ANRO Position: Q1 2026 in Review

UBS Group reduced its Alto Neuroscience (ANRO) stake by 6.7% in Q1 2026, selling an estimated $23K and leaving 17,250 shares worth $388K. The position accounts for ﹤0.01% of the portfolio, ranked #6252.

UBS Group first reported a position in ANRO in Q1 2024 and has held it in 9 quarters since. The position peaked at $1.7M in Q4 2024. 110 funds tracked by Wall St. Rank hold ANRO as of Q1 2026.

  • UBS Group held 17,250 shares of Alto Neuroscience worth $388K as of Q1 2026.
  • UBS Group sold 1,239 Alto Neuroscience shares in Q1 2026, an estimated $23K.
  • Alto Neuroscience made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6252 holding.
  • UBS Group first reported a position in Alto Neuroscience in Q1 2024 and has held it in 9 quarters since.
  • UBS Group's Alto Neuroscience position peaked at $1.7M in Q4 2024.
  • 110 funds tracked by Wall St. Rank held Alto Neuroscience as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.